Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978199 | 0.80 | CA1 (0.35) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL26026002 | 0.75 | TDP1 (0.39) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL24890940 | 0.75 | TDP1 (0.39) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18939701 | 0.74 | TDP1 (0.50) | TDP1MEN1KMT2ATSHRMAOA | |
| SCHEMBL22821066 | 0.71 | TDP1 (0.41) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4712142 | 0.71 | TDP1 (0.47) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL15592200 | 0.70 | TDP1 (0.46) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL19143260 | 0.69 | MEN1 (0.41) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL24890937 | 0.69 | MEN1 (0.41) | TDP1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18681191 | 0.69 | IDO1 (0.43) | TDP1MEN1KMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | TDP1 1201/4885MEN1 3988/4885KMT2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.